70842-33-0

Usage

Uses

Used in Organic Synthesis:
3-Chloro-5-ethoxy-4-hydroxybenzaldehyde is used as a key intermediate in organic synthesis for the production of various chemical compounds. Its functional groups allow for a wide range of chemical reactions, making it a versatile building block in the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3-chloro-5-ethoxy-4-hydroxybenzaldehyde is used as an intermediate in the synthesis of various drugs. Its unique structure and functional groups enable the development of new pharmaceutical compounds with potential therapeutic applications.
Used in Agrochemical Industry:
3-Chloro-5-ethoxy-4-hydroxybenzaldehyde is also utilized in the agrochemical industry as an intermediate for the production of pesticides and other agrochemicals. Its chemical properties make it suitable for the development of effective and targeted agrochemical products.

InChI:InChI=1/C9H9ClO3/c1-2-13-8-4-6(5-11)3-7(10)9(8)12/h3-5,12H,2H2,1H3

Upstream product

• 121-32-4 4-hydroxy-3-ethoxybenzaldehyde 

Downstream Products

• 1350612-59-7 (5Z)-5-(3-chloro-5-ethoxy-4-hydroxybenzylidene)-2-(4-chlorophenylimino)-3-methylthiazolidin-4-one 
• 1350612-61-1 3-((Z)-5-(3-chloro-5-ethoxy-4-hydroxybenzylidene)-3-methyl-4-oxothiazolidin-2-ylideneamino)benzoic acid 
• 1350612-60-0 methyl 5-((Z)-5-(3-chloro-5-ethoxy-4-hydroxybenzylidene)-3-methyl-4-oxothiazolidin-2-ylideneamino)-2-chlorobenzoate 
• 1350612-58-6 5-((Z)-5-(3-chloro-5-ethoxy-4-hydroxybenzylidene)-3-methyl-4-oxothiazolidin-2-ylideneamino)-2-chlorobenzoic acid 

Relevant academic research and scientific papers

SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS

Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.

HL005 - A new selective PPARγ antagonist specifically inhibits the proliferation of MCF-7

Peroxisome proliferator-activated receptor-γ (PPARγ) is a nuclear transcription factor which is involved in many diseases, such as diabetes, inflammation, dyslipidemia, hypertension, and cancer. Recently, there are many reports showing that PPARγ agonists have preclinical and clinical anticancer activity, with relatively few reports on anticancer effects of PPARγ antagonists. From our compound library, a novel 3-thiazolinone- modified benzoic acid derivative HL005 is found as PPARγ selective ligand through SPR analysis (KD = 0.21 μM), yeast two-hybrid results suggest that HL005 antagonize the potent PPARγ agonist rosiglitazone-induced recruitment of the coactivator for PPARγ (IC 50 = 7.97 μM). Different from the most reported PPARγ antagonist, HL005 can inhibit the proliferation of MCF-7 cell line in a concentration-dependent manner and induce cell cycle arrest at G2/M phase, other than interference with cell adhesion. In order to study the binding mode of this compound, three derivatives are synthesized to get more detail about the structure-activity relationship, molecular docking and the NMR spectra indicate that similar to most PPARγ ligand, the carboxylic acid group is an important moiety for HL005 and contributes strong interaction with PPARγ.